Clinical Trials
Clinical trials are research studies designed to see if a new treatment is safe and effective. JSG offers clinical trials through our partner, Susquehanna Research Group (SRG).
Clinical Trials Through JSG & SRG
Clinical trials are used to evaluate if a new treatment is more effective and/or has fewer side effects than the standard treatment. Clinical Trials also give patients access to the latest innovations in care. We are excited to offer these opportunities to our qualified patients. You can read more about our sites active clinical trials below and at ClinicalTrials.gov.
Clinical Trials Available at JSG
The trial records located in the National Institute of Health’s U.S. National Library of Medicine include eligibility criteria, the intervention or treatment, completion dates and more information. JSG currently has active clinical trials available to our patients. Learn more about the individual trails below.
ProCares »
- This study will enroll individuals 45 years of age or older who present with symptoms, signs, and/or have findings leading to a clinical suspicion (but not yet diagnosed) OR newly diagnosed cancer of the following types of cancer:
- Biliary Tract, Colon, Esophagogastric Junction, Esophagus, Gallbladder, Head and Neck, Liver, Lung, Lymphatic System, Ovary, Pancreas, Rectum, Stomach
- One time blood collection
- No prior cancer history
- Newly diagnosed cancer must be enrolled into the study within 45 days of diagnosis
Sanofi Crohn’s »
- Moderate to severe active Crohn’s
- Unique, first in class, Nanobody therapeutic protein directed at TNF and OX40L (which plays a role in T-helper cell differentiation and maintenance)
- SC injections Q2weeks
- Biologic naïve and failed standard treatment OR failed at least 1 biologic/advanced therapy therapy class but not more than 3
- No fistulizing disease, ostomy or ileoanal pouch or missing more than 2 entire segments of colon
- No opiate use or cannabis use (even if for medical reasons)
- Total study length: 52 weeks with additional Open Label Period of 104 weeks
Sanofi UC »
- Moderate to severe, active UC with rectal bleeding
- Unique, first in class, Nanobody therapeutic protein directed at TNF and OX40L (which plays a role in T-helper cell differentiation and maintenance)
- SC injections Q2weeks
- Biologic naïve and failed standard treatment OR failed at least 1 biologic/advanced therapy class
- No ileal pouch or ostomy
- No diagnosis of inflammatory conditions other than UC (including but not limited to systemic lupus erythematosus, systemic sclerosis, myositis, rheumatoid arthritis, primary biliary cirrhosis, multiple sclerosis, Behcet’s disease, sarcoidosis, etc)
- Total study length: 52 weeks with additional Open Label Period of 104 weeks
T-Scan- UC »
- Ulcerative colitis- currently symptomatic
- Blood only- one time visit
- Biologic meds are allowed
- NO– drugs that are known to be T cell toxic. The following treatments are not allowed and include:
- Glucocorticoids including prednisone, methylprednisolone (Solumedrol), budesonide (Entocort), hydrocortisone (Solu-cortef), dexamethasone (Decadron), betamethasone (Betaject)
- Sulfasalazine (Azulfidine)
- Aminosalicylates including mesalamine/ mesalazine (Asacol, Pentasa).
- Thiopurines including azathioprine (Imuran) and 6-mercaptopurine (Purixan)
- Systemic JAK inhibitors including tofacitinib (Xeljanz), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq)
- Methotrexate
Idiopathic Gastroparesis CIN-102-124 »
- (Deudomperidone) in Adult Subjects with Idiopathic Gastroparesis
- Daily nausea
- At least 1 episode of vomiting in a 2-week period
- NO diabetic patients permitted
T-Scan- Crohn’s »
- Crohn’s with upcoming endoscopy procedure scheduled
- Biologic meds are allowed
- NO– drugs that are known to be T cell toxic. The following treatments are not allowed and include:
- Glucocorticoids including prednisone, methylprednisolone (Solumedrol), budesonide (Entocort), hydrocortisone (Solu-cortef), dexamethasone (Decadron), betamethasone (Betaject)
- Sulfasalazine (Azulfidine)
- Aminosalicylates including mesalamine/ mesalazine (Asacol, Pentasa).
- Thiopurines including azathioprine (Imuran) and 6-mercaptopurine (Purixan)
- Systemic JAK inhibitors including tofacitinib (Xeljanz), abrocitinib (Cibinqo), baricitinib (Olumiant), upadacitinib (Rinvoq)
- Methotrexate
CRC or Advanced Adenoma – Exact Sciences »
- Age 18 or older
- Newly diagnosed CRC- not yet treated
- Advanced Adenoma (>1cm remaining and biopsy proven) requiring follow up intervention
C-Diff- Vedanta »
- For patients with C-Diff who have had at least one prior occurrence of C-Diff within the last 6 months
- VE303 is an oral, live biotherapeutic (taken in capsule form x 14 days) that will be administered following completion of a course of standard-of-care (SoC) antibiotics
Crohn’s- Abivax »
- Moderate to severely active Crohn’s disease
- ABX464 is an oral, novel anti-inflammatory drug
- Documented inadequate response (defined as lack of response or loss of response or intolerance) to at least one of the following treatments: corticosteroids (CS), immunosuppressants (IS), biologic or biosimilar therapies, or JAK
- Subjects may receive study drug for up to 100 weeks
EOE- NSI-8226-201- Uniquity One »
- Diagnosis of EOE by endoscopic biopsy prior to screening, as demonstrated by intraepithelial eosinophilic infiltration (peak cell count ≥ 15 eosinophils/hpf from at least 1 esophageal region)
- Participant reported weekly dysphagia in the last 4 weeks
- Participants with previously documented standard of care treatment, which could include proton pump inhibitors (PPIs), swallowed topical corticosteroids (STCs), and/or diet, must agree not to change background medication
- The study drug, Solrikitug, will be administered SC Q4 weeks
EOE-Dupixent Registry
- A U.S. Registry of EOE patients treated with Dupixent as standard of care
- Any patient being prescribed Dupixent for EOE should be invited to participate in the registry.
- Patients should be enrolling into the study on the day of or PRIOR to first dose of Dupixent
- NO treatment with Dupixent within the 6 months prior to screening
- Total study length: 36 months (3 years) with 9 visits- all remote